Injectable-grade GHK-Cu sold in the research peptide market is explicitly labelled "not for human consumption," which isn't a legal formality, it reflects that this supply chain sits outside pharmacopeial oversight
Phase 2 dose-finding data The phase 2 trial tested cagrilintide at 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg weekly
Home Explore View Cart Deals Saved Suggested searches Plant-based protein powders Vegan leather handbags Bedroom decor Waterproof jackets Hoodies Learn more about how we use your data to personalize your experience and ads
Not for use on sensitive skin
Studies demonstrate protection against gastric ulcers, intestinal damage, and inflammatory bowel conditions
This makes for a more consistent and reproducible research protocol, which is the bedrock of good science